REG - Hemogenyx Pharma Plc - Equity Incentive Pool Increase and Option Grant

Hemogenyx PharmaceuticalsAnnouncement

28/04/2023 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230428:nRSb8828Xa&default-theme=true

RNS Number : 8828X  Hemogenyx Pharmaceuticals PLC  28 April 2023

28 April 2023

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

Equity Incentive Plan Pool Increase and Grant of Share Options

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that the Company's Board
of Directors has resolved to increase the pool for the granting of share
options, restricted shares, and restricted share units under the Company's
2021 Equity Incentive Plan with Non-Employee Sub-Plan by 60,000,000 shares,
amounting to a total pool of 90,000,000 shares.

The Company has also granted a total of 57,099,966 options over ordinary
shares in the capital of the Company ("Share Options") to the Company's
co-founder and CEO, Dr Vladislav Sandler. The Share Options vest in two
tranches of 22,839,986 Share Options ("Tranche 1") and 34,259,980 Share
Options ("Tranche 2"). The Tranche 1 Share Options are being granted in
recognition of Dr Sandler's work in bringing HEMO-CAR-T to the point of
preparing it for submission of an Investigational New Drug ("IND") application
to the US Food and Drug Administration ("FDA") for approval. The Tranche 2
Share Options will vest upon authorization by the FDA for the Company to
commence clinical trials of HEMO-CAR-T.

The details of the Share Options granted are set out below:

 Name                  Position  Number of Share Options Granted  Exercise Price (pence)  Vesting Date/Criteria                                                     Expiry Date
 Dr Vladislav Sandler  CEO       22,839,986                       Tranche 1:              Tranche 1: immediately                                                    Tranche 1: 27 April 2028

2.5p

                                 34,259,980
                                                                                                 Tranche 2: 5 years from vesting date
                                                                  Tranche 2:

2.875p                 Tranche 2: upon authorisation by the FDA to commence clinical trials of
                                                                                          HEMO-CAR-T

 

Following the grant of the Share Options, there are, in aggregate, 92,399,552
ordinary shares of 1 penny each in the Company under option held by directors,
employees and members of the Scientific Advisory Board of the Company arising
from awards made under the Company's original Employee Plan, Non-Employee Plan
and the 2021 Equity Incentive Plan with Non-Employee Sub-Plan. These represent
8.09% of the issued ordinary share capital of the Company.

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                    https://hemogenyx.com (https://hemogenyx.com/)
 Peter Redmond, Director                          peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                   Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                       Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMR") and persons closely associated with them
("PCA"):

 1.  Details of PDMR/person closely associated with them
 a)  Name                                     Dr Vladislav Sandler
 b)  Position/status                          CEO, Executive Director
 c)  Initial notification/                    Initial notification

amendment
 2.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc

Identification code GB00BYX3WZ24
 b)  Nature of the transaction                Grant of options
 c)  Price(s) and volume(s)                   Price(s)    Volume(s)
                                              1. 2.5p     1.   22,839,986

                                              2. 2.875p   2.   34,259,980

 

 d)  Aggregated information                   Price(s)        Volume(s)

                                        N/A - variable  57,099,966
     -     Aggregated volume

     -     Price
 e)  Date of the transaction                  28/04/2023
 f)  Place of the transaction                 Outside of a trading venue

 

 

d)

Aggregated information

-     Aggregated volume

-     Price

 Price(s)        Volume(s)
 N/A - variable  57,099,966

e)

Date of the transaction

28/04/2023

f)

Place of the transaction

Outside of a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEKZGZDRRLGFZG